The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

If you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Katrina Cooke and Ashley Dostefano share their personal journeys, reflecting on the challenges they faced, the victories they ...

Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...